Rethink Impact is the largest, US-based impact venture capital firm with a gender lens that invests in female leaders using technology to solve the world’s biggest problems. We believe that the next generation of extraordinary companies (in health, environmental sustainability, education, and economic empowerment) will find success through their relentless pursuit of mission, for the benefit of all communities. We seek mission-driven founders and teams leveraging breakthrough innovations in technology for the benefit of people and planet. Our primary focus is on companies with female CEOs, or in some cases, women in C-level roles (e.g. CTO, COO, CRO, or CFO). We write $2M-$10M checks to lead or co-invest in Late Seed–Series C rounds. We look for companies with $500K-$15M in annual recurring revenue that are on a path to grow to $50M-$100M in the next five years (although, we will invest in later-stage deals where we believe we can have a significant impact and where the company is a fit for our mission more broadly). We have a bias towards capital-efficient, software solutions and marketplaces solving critical problems for businesses (B2B and B2B2C) and, ultimately, the communities they serve. We are actively sourcing investments that are making new digital health and education innovations broadly accessible to improve outcomes and reduce costs, providing tools for individuals and families to move up the economic ladder, and speeding the transition to a more sustainable and resource-efficient economy. We work to actively support our portfolio companies, helping them with everything from their next round of financing to leveraging their mission as a competitive advantage in hiring, growth, and brand building.

Rethink Impact

Atlantic Street Capital Management, LLC is a private equity firm specializing in lower middle market companies in buyouts, recapitalizations, corporate carve-outs, restructurings, and bankruptcies.  Atlantic Street Capital Management, LLC was founded in 2006 and is headquartered in Stamford, Connecticut.

Atlantic Street Capital

Univfy

The Univfy AI Platform helps women and couples navigate their family-building options with cost-savings, greater success, and a simplified experience. Univfy combines AI/machine learning, clinical expertise, and empathy to maximize each patient’s chances of success with assisted reproductive technology such as in vitro fertilization (IVF) while increasing growth and efficiency for physicians.  Univfy is the only highly-scalable AI platform to provide scientifically-validated, personalized reports that counsel patients from diverse demographics about their probability of having a baby with IVF. Through technology developed by Stanford University researchers, Univfy uses a rigorous scientific process to develop and validate prediction models and to provide essential information to support better budgeting, planning, and physician-patient shared decision-making. Its methods have been published in the top, peer-reviewed research publications, setting a gold standard for IVF success model performance metrics. Univfy has a global IP portfolio, comprising patents issued in the US and other countries.

<div>Univfy leverages artificial intelligence and machine learning (AI/ML) technology, developed at Stanford University, to make fertility care more accessible for patients. The company uses a scientific approach to develop and validate clinical live birth outcomes using each fertility clinic’s data, supporting patient counseling at fertility centers across the US, Canada, and European Union.</div>

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Univfy Raises $6 Million in Series B Financing to Expand Fertility Benefits

<div>
 
 Univfy leverages artificial intelligence and machine learning (AI/ML) technology, developed at Stanford University, to make fertility care more accessible for patients. The company uses a scientific approach to develop and validate clinical live birth outcomes using each fertility clinic’s data, supporting patient counseling at fertility centers across the US, Canada, and European Union.
 
 
 Fertility specialists use the company’s flagship product—the unified Univfy PreIVF Report to provide personalized counseling to patients on the benefits and limitations of IVF treatments, the probability of having a baby through IVF, transparent insights on fertility treatment costs, and recommendations on other fertility treatments. Univfy PreIVF Report is more data-driven as it incorporates data about the patient’s unique characteristics including age, anti-müllerian hormone (AMH), and other factors related to fertility. Univfy’s personalized fertility prognostics help fertility centers to provide value-based pricing programs that meet the financial requirements of their patients. Univfy also offers refund programs to improve the patient’s chances of success while lowering IVF-related costs.
 
 
 In December 2021, the company raised USD 6 million in a Series B funding round led by Atlantic Street Capital. The company expected to utilize the funds to extend its suite of services to health plan providers and employers.
 
</div>

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

Univfy

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless